首页 | 本学科首页   官方微博 | 高级检索  
   检索      


A mutation in β‐tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel‐resistant prostate cancer cell line
Authors:Takahito Hara  Kazutaka Ushio  Mayumi Nishiwaki  Jin Kouno  Hideo Araki  Yukiko Hikichi  Masahiko Hattori  Yumi Imai  Masuo Yamaoka
Institution:1. Pharmacology Research Laboratories, Takeda Pharmaceutical Company Limited, Tsukuba, Japan;2. Discovery Research Center, Takeda Pharmaceutical Company Limited, Osaka, Japan
Abstract:The mechanisms of docetaxel resistance in PC (prostate cancer) are unclear because of the lack of suitable experimental models, and no effective treatment exists for docetaxel‐resistant PC. We established a docetaxel‐resistant cell line, LNDCr, from an androgen‐refractory PC cell line, LNCaP‐hr, by intermittent exposure to docetaxel in vitro. The LNDCr cells harboured an F270I mutation in class I β‐tubulin, and demonstrated impaired tubulin polymerization by docetaxel. AR signalling was sustained in LNDCr cells, and AR knockdown suppressed the growth of LNDCr cells. These results suggest that an acquired mutation in β‐tubulin is associated with docetaxel resistance in PC and that a novel AR‐targeted therapy is effective for docetaxel‐resistant PC.
Keywords:androgen receptor  docetaxel  drug resistance  prostate cancer  tubulin
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号